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Abstract Single-domain antibody fragments (VHHs) have
several beneficial properties as compared to conventional
antibody fragments. However, their small size complicates
their toxin- and virus-neutralizing capacity. We isolated 27
VHHs binding Escherichia coli heat-labile toxin and
expressed these in Saccharomyces cerevisiae. The most
potent neutralizing VHH (LT109) was N-glycosylated,
resulting in a large increase in molecular mass. This suggests
that N-glycosylation of LT109 improves its neutralizing
capacity. Indeed, deglycosylation of LT109 decreased its
neutralizing capacity three- to fivefold. We also studied the
effect of glycosylation of two previously isolated VHHs on
their ability to neutralize foot-and-mouth disease virus.
For this purpose, these VHHs that lacked potential N-
glycosylation sites were genetically fused to another VHH
that was known to be glycosylated. The resulting fusion
proteins were also N-glycosylated. They neutralized the
virus at at least fourfold-lower VHH concentrations as
compared to the single, non-glycosylated VHHs and at at
least 50-fold-lower VHH concentrations as compared to
their deglycosylated counterparts. Thus, we have shown
that N-glycosylation of VHHs contributes to toxin- and
virus-neutralizing capacity.
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Introduction
Camelids produce antibodies that are naturally devoid of
light chains (Hamers-Casterman et al. 1993). The single N-
terminal domains of these heavy-chain antibodies (VHHs)
are fully capable of antigen binding. They have several
advantages for biotechnological purposes, such as a high
physicochemical stability, a high production level in
microorganisms, and the facile construction of genetic
fusions of two VHH domains (Harmsen and De Haard
2007). As a result, there is currently much interest in
various therapeutic applications of VHHs (Harmsen and De
Haard 2007; Saerens et al. 2008).
The mechanism of action of therapeutic antibody frag-
ments is often based on blocking the interaction of their
cognate antigen with a specific receptor. This is exemplified
by antibodies neutralizing heat-labile toxin (LT), which is
secreted by enterotoxigenic E. coli, and the closely related
cholera toxin (CT), produced by Vibrio cholerae. Both
toxins (reviewed by Spangler 1992) cause diarrheal
diseases and belong to the AB5 toxin family. The five B-
subunits are responsible for holotoxin binding to the
monosialoganglioside (GM1) receptor on intestinal epithe-
lial cells (Cuatrecasas 1973) after which the single A
subunit is injected into the cells (Holmgren 1981).
Neutralizing antibodies generally bind to the B-subunit
and block receptor interaction (Apter et al. 1993). Similarly,
virus neutralization by antibodies predominantly relies on
the ability to block the interaction between the virion and a
specific cellular receptor (Parren and Burton 2001). Such
blocking may occur due to direct binding to a viral epitope
involved with receptor interaction. Consistent with this we
observed that most potent foot-and-mouth disease virus
(FMDV) neutralizing VHHs recognized an epitope called
the GH-loop (Harmsen et al. 2007), which binds to the
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e-mail: michiel.harmsen@wur.nlcellular receptor. Alternatively, binding of a bulky antibody
close to a site involved with receptor interaction may also
prevent receptor interaction, a process called steric hin-
drance (Mateu and Verdaguer 2004).
Due to their small size, VHHs are probably less well
suited for steric hindrance. Increasing the size of VHHs by
N-glycosylation could increase their neutralizing capacity. N-
glycosylation occurs at Asn-X-Ser/Thr sequons, where X
represents any amino acid except Pro. About 90% of such
sites become N-glycosylated (Gavel and von Heijne 1990).
About 10% of the VHHs have such potential N-glycosyla-
tion sites (Harmsen et al. 2000). N-glycosylation is a
complex sequential process involving the transfer of a core-
oligosaccharide to the protein within the endoplasmic
reticulum and the addition of an outer-chain oligosaccharide
within the Golgi apparatus. In mammals, the type of outer-
chain glycosylation is highly variable between different
proteins and sites and can be classified into high-mannose,
hybrid, and complex-type glycosylation. Baker’sy e a s t( S.
cerevisiae) only adds outer chains consisting of α1–3- and
α1–6-linked mannose residues. Depending on the particular
glycosylation site, such yeast outer-chain glycosylation can
result either in relatively short chains of about 10 kDa (core-
like N-glycosylation) or very long chains with different
lengths (high-mannose-type N-glycosylation) that have a
molecular mass of 50–100 kDa (Kukuruzinska and Lennon
1998). As a result, yeast N-glycosylation of small proteins
such as VHHs that have an average size of 15 kDa, can
result in a large increase in molecular mass.
We therefore analyzed the contribution of N-glycosyla-
tion of VHHs to their neutralizing capacity. We isolated
several LT-binding VHHs and produced them by secretory
yeast expression. A potent LT-neutralizing VHH was found
to be N-glycosylated. We have further shown that its
glycosylation contributes to its neutralization. We also
showed that we could increase the FMDV-neutralizing
capacity of two non-glycosylated VHHs by genetic fusion
to another VHH that is glycosylated. The possible
mechanism by which N-glycosylation improves neutraliza-
tion capacity of VHHs is discussed.
Materials and methods
Strains and genetic constructs
E. coli XL1-Blue (Stratagene, La Jolla, CA) was used for
routine recombinant DNA manipulation. E. coli TG1
(Stratagene) was used for phage display purposes. S.
cerevisiae SU51 (YT6-2-1L) MATa; can1; his4-519; leu2-
3, −112; cir
+, which is a cir
+ derivative of AH22 (ATCC
38626), was used for VHH production as described
previously (Van der Vaart 2002).
Phage display selection of LT-binding VHHs
The basic procedure for selection of antigen specific VHHs
from immunized llamas by phage display using vector
pUR4676 has been described before (Frenken et al. 2000;
Harmsen et al. 2002). We immunized a single llama with
100 µg LT (Sigma, Saint Louis, MO) per immunization.
Phage display selections of clones producing LT-binding
VHHs were performed by biopanning (McCafferty and
Johnson 1996), using polystyrene 96-well plates coated
with 0.1 or 0.01 µg/ml LT (Sigma). The VHH encoding
regions of clones binding LT in ELISA were subjected to
automated DNA sequencing as described previously
(Harmsen et al. 2000). The deduced VHH amino acid
sequences were aligned according to the IMGT system
(Lefranc 2004) for alignment, numbering, and
complementarity-determining region (CDR) definition of
immunoglobulins. Additional gaps had to be introduced at
the end of CDR2 to accommodate VHHs with unusually
long CDR2s.
Yeast production of VHHs
LT-binding VHHs containing a C-terminal hexahistidine tag
were produced by secretory yeast expression using plasmid
pUR4584 and yeast strain SU51 (Harmsen et al. 2005b).
For this purpose, VHH clones were transferred from
pUR4676 to pUR4584 using the PstI and BstEII restriction
sites. Single FMDV-binding VHHs M180 and M200 and
the porcine immunoglobulin G binding VHH VI-12 were
produced as described previously using vector pUR4585
(Harmsen et al. 2007) with C-terminal c-myc and hexahis-
tidine tags. The VHH2s M180shVI-12 and M200shVI-12
were produced as described previously (Harmsen et al.
2005a), but using the llama short-hinge sequence without
cysteines (amino acid sequence AHHSEDPSSKSP) instead
of the synthetic Gly–Gly–Ser linker for fusion of the two
VHH domains. Secreted VHHs or VHH2s were purified by
immobilized-metal affinity chromatography as described
previously (Harmsen et al. 2005b). VHHs were deglycosy-
lated by 16 h incubation of 5 mg/ml VHH with 2 U/ml
endoglycosidase H (Roche Applied Science, Mannheim,
Germany) at 37 °C in 50 mM sodium citrate, pH 5.5.
Vero cell assay
The cytopathogenic effect (CPE) of LT on African green
monkey kidney (Vero) cells was used to measure LT
toxicity (Speirs et al. 1977). Monolayers of Vero cells were
grown in Minimal Essential Medium Eagles with Earle’s
salts and L-glutamine (EMEM; Invitrogen, San Diego, CA)
and containing 10% normal calf serum in 96-well plates at
37 °C in a 5% CO2 atmosphere. The ability of VHHs to
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100 µl 1 µg/L LT in Medium 199 without serum
(Invitrogen) with a twofold dilution series of 10 mg/L
VHH for 1 h at 37 °C. These mixtures were then transferred
to the Vero cell monolayers. After a further 24-h incubation
at 37 °C in a 5% CO2 atmosphere, the percentage of cells
showing a CPE was microscopically determined. The VHH
concentration required to inhibit the CPE on 75% of the
cells was then determined.
ELISAs
GM1, LT, CT, and the CT subunits A (CTA) and B (CTB)
were all obtained from Sigma. For all ELISAs, high-binding
polystyrene 96-well plates (Greiner, Solingen, Germany)
were coated overnight at 4 °C with proteins in 50 mM
carbonate/bicarbonate buffer, pH 9.6. LT was biotinylated
using aminohexanoyl-biotin-N-hydroxysuccinimide (Zymed,
San Francisco, CA) at a protein to biotin ratio of 100 on a
weight basis.
The ability of VHHs to bind LTor CT holotoxins or their
subunits was determined by incubation of plates coated
with 1 mg/L of these antigens with twofold dilution series
of 10 mg/L VHH in ELISA-buffer (1% skimmed milk;
0.05% Tween-20; 0.5 M NaCl; 2.7 mM KCl; 2.8 mM
KH2PO4; 8.1 mM Na2HPO4; pH 7.4). Bound VHH was
detected with peroxidase-conjugated polyclonal rabbit
immunoglobulins anti-llama-immunoglobulin (Frenken et
al. 2000) and staining with 3,3′,5,5′ tetramethylbenzidine
(TMB). The VHH concentration resulting in an extinction
at 450 nm of 0.3 was then determined by nonlinear
regression analysis.
The ability of anti-LT VHHs to inhibit binding of LT to
GM1 was determined using an inhibition ELISA. Serial
twofold dilution series of 10 mg/L VHH were preincubated
with 0.1 mg/L biotinylated LT in 100 μl PBS containing
1% ovalbumin (Sigma; grade V) and 0.05% Tween-20 for
1 h at room temperature. These mixtures were then
transferred to a plate coated with 0.2 mg/L GM1 and
incubated for another hour. Bound biotinylated LT was then
detected using peroxidase-conjugated streptavidin (Jackson
Immunoresearch, West Grove, PA) and staining with TMB.
The 50% inhibitory concentration (IC50) was calculated by
interpolating the VHH concentration resulting in 50% of
the extinction value obtained by a control incubation
without VHH.
SDS-PAGE
VHHs (1 μg) were subjected to reducing SDS-PAGE, using
precast gels (Novex, San Diego, CA), and stained using
Sypro Orange and a STORM fosfor imager (Molecular
Dynamics, Sunnyvale, CA).
In vitro FMDV neutralization assay
VHH concentrations required for neutralization of FMDV
O1 Manisa were determined as described previously
(Harmsen et al. 2007) using 20 tissue culture infective
doses required to infect 50% of the wells (TCID50)i n
duplicate assays using monolayers of secondary swine
kidney cells and serial twofold dilutions of 10 mg/ml
VHHs. When using endoglycosidase-H-treated VHH(2)s,
we used a starting concentration of 1 mg/ml VHH(2).
Nucleotide sequence accession numbers
Nucleotide sequences of selected anti-LT VHHs were
submitted to the EMBL database under accession numbers
AJ849409–AJ849413, AJ849415–AJ849427, AJ849431–
AJ849438 and AJ849442 (Fig. 1).
Results
Isolation of LT-binding VHHs
We isolated 180 clones producing VHHs that bound LT in
ELISA by phage display selection from an immunized
llama. After fingerprinting and sequence analysis, we
obtained 27 unique VHHs (Fig. 1). Antibody variable
domains, including VHHs, contain three complementarity-
determining regions (CDRs) that are often directly involved
in antigen binding (Muyldermans et al. 2001). CDR3
generally is most variable (Harmsen et al. 2000). Many of
the 27 clones had similar CDR3 sequences, allowing the
dissection into 11 CDR3 groups (A-K, Fig. 1).
Antigenic specificity of LT-binding VHHs
The 27 unique VHHs were expressed in yeast and
purified. The VHH concentration required to inhibit 75%
(IC75) of the toxic effect of LT in a Vero cell assay ranges
from more than 10 mg/L for non-neutralizing clones to
0.0017 for clone LT109 (Table 1). Most neutralizing
clones also inhibited binding of LT to its cellular receptor
GM1, as determined by ELISA. Clone LT109 again had
the lowest IC50 (Table 1). The subunit specificity of LT-
binding VHHs was determined using the commercially
available subunits of the related CT. Most clones cross-
reacted sufficiently to CT holotoxin to enable such
determination (Table 1). These VHHs required a similar
VHH concentration for binding to the CT B-subunit and
holotoxin, suggesting that they bind the B-subunit. The
subunit specificity of LT104 and LT139 could not be
determined due to insufficient cross reaction with CT
(Table 1).
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The VHHs LT109 and LT156 have potential N-glycosylation
sites at IMGT positions 61 and 62, respectively, which are
both located in CDR2 (Fig. 1). SDS-PAGE analysis showed
that LT109 indeed consisted of a heterogeneous high-
molecular-weight species, indicative of high-mannose type
N-glycosylation, in addition to a minor amount of a discrete
Fig. 1 Multiple amino acid sequence alignment of E. coli LT-binding
VHHs. Dashes indicate gaps introduced for sequence alignment. Dots
indicate amino acids identical to the consensus sequence. Residue
numbering and CDR definitions are according to the IMGT
numbering system (Lefranc 2004). Residues 1–5( a m i n oa c i d
sequence QVQLQ) and 143–145 (amino acid sequence VSS) are not
shown since they are vector-encoded. The VHH clones are ranked
according to CDR3-group and clone number. VHHs of the same
CDR3 group are boxed. Potential N- glycosylation sites are indicated
in boldface
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unglycosylated VHH (Fig. 2a). Deglycosylation of LT109 by
endoglycosidase H treatment resulted in only this 15-kDa
species, confirming that LT109 is partially glycosylated
(Fig. 2q). Densitometric comparison of bands representing
glycosylated and deglycosylated LT109 revealed that about
98 % of LT109 is glycosylated. A similar analysis revealed
that LT156 is not glycosylated (Fig. 2a).
Deglycosylation of LT109 resulted in a fivefold-
increased IC75 in a Vero cell assay and a threefold-
increased IC50 in a GM1-LT inhibition ELISA (Table 1),
indicating that N-glycosylation of LT109 contributes to its
LT-neutralizing capacity.
Enhancement of virus neutralization by glycosylation of VHHs
We next analyzed the effect of VHH glycosylation on virus
neutralization. For this purpose, we used two previously
isolated FMDV-binding VHHs, M180, and M200, that lack
potential N-glycosylation sites and neutralize FMDV in
vitro (Harmsen et al. 2007). These VHHs were genetically
fused to a porcine IgG binding VHH, VI-12, that contains a
high-mannose-type N-glycan at position 28 (Harmsen et al.
2005a). Both yeast-produced genetic fusions (VHH2s) were
also efficiently glycosylated as revealed by analysis of
endoglycosidase H-treated and untreated samples (Fig. 2b).
These glycosylated VHH2s neutralized FMDV at at least
fourfold-lower concentrations than observed with the
corresponding individual FMDV-binding VHHs and at at
least 50-fold-lower concentrations than their deglycosylated
counterparts (Table 2). This shows that VHH glycosylation
contributes to FMDV neutralization.
Discussion
After isolating 27 VHHs binding to E. coli LT, a single yeast-
expressed clone, LT109, was found to be N-glycosylated at a
Clone Vero cell assay IC75 GM1-LT ELISA IC50 Titer in ELISA (mg/L)
Mean ± SD
a (mg/L) Mean ± SD (mg/L) LT CT CTB CTA
LT105 >10
b ±0 >10 ±0 0.073 1.3 0.26 >10
LT106 3.3 ±0 0.028 ±0.003 0.032 0.25 0.12 >10
LT109 0.0017 ±0.0012 0.021 ±0.008 0.18 0.12 0.15 >10
LT109 endoH
c 0.0084 ±0.005 0.06 ±0.024 ND
d ND ND ND
LT128 >10 ±0 >10 ±0 0.002 0.098 0.027 >10
LT131 6.7 ±4.7 >10 ±0 0.023 0.023 0.012 >10
LT132 >10 ±0 >10 ±0 0.020 0.024 0.013 >10
LT141 3.3 ±0 >10 ±0 0.038 0.019 0.016 >10
LT143 >10 ±0 >10 ±0 0.028 0.040 0.016 >10
LT101 >10 ±0 0.91 ±0.34 0.042 4.6 1.6 >10
LT104 >10 ±0 7.2 ±4.9 0.010 >10 8.6 >10
LT111 1.1 ±0 0.67 ±0.26 0.042 3.1 0.83 >10
LT116 >10 ±0 1.5 ±1.4 0.010 0.66 0.21 >10
LT133 >10 ±0 8.5 ±6.4 0.059 4.1 1.6 >10
LT129 0.21 ±0.23 0.81 ±0.14 0.20 3.6 2.9 >10
LT139 >10 ±0 0.18 ±0.11 0.059 8.1 >10 >10
LT103 0.74 ±0.52 0.86 ±0.29 0.16 0.13 0.071 >10
LT124 0.12 ±0 0.27 ±0.11 0.054 0.037 0.033 >10
LT130 0.21 ±0.23 0.78 ±0.01 0.035 0.032 0.023 >10
LT154 0.39 ±0.03 0.96 ±1.02 0.048 0.022 0.016 >10
LT155 0.02 ±0.009 0.21 ±0.25 0.028 0.014 0.010 >10
LT156 0.17 ±0.06 2.1 ±2.5 0.024 0.019 0.010 >10
LT161 0.27 ±0.21 2.9 ±3.6 0.20 0.061 0.026 >10
LT163 0.07 ±0.05 0.18 ±0.03 0.038 0.026 0.024 >10
LT165 0.03 ±0.01 0.09 ±0.02 0.12 0.042 0.043 >10
LT176 1.1 ±0.00 1.2 ±0.39 0.040 0.030 0.023 >10
LT168 1.4 ±0.39 0.03 ±0.00 0.057 0.042 0.038 >10
LT170 0.39 ±0.03 0.03 ±0.01 0.073 0.048 0.038 >10
Table 1 Toxin neutralization
and antigenic specificity of LT-
binding VHHs
aSD, standard deviation
b >10, the VHH showed no
effect at the highest concentra-
tion analyzed (10 mg/L)
cendoH, sample that was degly-
cosylated by endoglycosidase H
treatment
dND, not determined
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efficiently, suggesting that its N-glycosylation contributes to
toxin neutralization. This is confirmed by the at least
threefold-decreased neutralization efficiency of enzymatically
deglycosylated LT109. About 98 % of the LT109 molecules
are glycosylated. Such partial glycosylation of sites is more
often observed (Kukuruzinska and Lennon 1998). The
presence of some unglycosylated LT109 complicates deter-
mination of the exact contribution of N-glycosylation to toxin
neutralization since the glycosylated VHH could bind to LT
with lower affinity. This is not unlikely since the glycosyl-
ation site of LT109 is located within CDR2, a region which is
often directly involved in antigen binding (Muyldermans et
al. 2001).
Most VHHs bound the B-subunit and their ability to
neutralize LT in vitro seemed to correlate with their ability
to inhibit toxin binding to the GM1 receptor, as measured
by an inhibition ELISA. This is consistent with previous
findings in the many studies on conventional monoclonal
antibodies against LT or CT, and the view that toxin
neutralization relies on inhibition of toxin receptor interac-
tion (Spangler 1992; Apter et al. 1993). Since LT contains
five GM1 binding sites (Sixma et al. 1992), neutralizing
VHHs must inhibit multiple receptor interactions. This can
be accomplished either by binding of multiple VHHs to a
single LT molecule or by blocking of multiple receptor sites
by a single VHH. In the latter case, an increased size of the
VHH due to N-glycosylation is likely to increase toxin
neutralization. Possibly, the glycosylation occurring close
to the antigen-binding site results in more efficient blocking
of toxin receptor sites as compared to glycosylation
occurring more distant from the antigen-binding site. It
remains to be determined whether glycosylation of VHHs
also increases inhibition of monovalent interactions.
We also assessed the effect of VHH glycosylation on
virus neutralization using two VHHs that are able to bind
FMDV. These VHHs naturally lacked potential glycosyla-
tion sites. They were indirectly glycosylated by genetic
fusion to another VHH that was known to be glycosylated.
This successful approach could generally be applied to
obtain glycosylation of VHHs. In both cases, the N-
glycosylation improved the FMDV neutralizing capacity
at least fourfold. One of these VHHs, clone M200, binds to
the GH-loop (Harmsen et al. 2007), which directly binds to
the cellular receptor. As a result, it is unlikely that the
increased neutralization relies on interference of the
oligosaccharide with the GH-loop to which the VHH binds.
However, each virion contains 60 GH-loop copies (Mateu
and Verdaguer 2004). Possibly, the increased neutralization
of the GH-loop-binding clone M200 due to N-glycosylation
results from steric hindrance of other GH-loop-receptor
interactions on the virion surface.
Protein glycosylation can also contribute to protein
stability after in vivo application (Sinclair and Elliott
2005). Since we studied the effect of neutralization in vitro
and because non-glycosylated VHHs already have a high
physicochemical stability (Van der Linden et al. 1999), it is
unlikely that the decreased toxin or virus neutralization by
deglycosylated VHHs results from reduced stability.
Parenteral application to mammals of proteins containing
terminally mannosylated carbohydrates, such as those occur-
Fig. 2 Analysis of glycosylation of VHHs a and VHH2s b by SDS-
PAGE. Samples were either treated (+) or mock-treated (−) with
endoglycosidase H (endoH). The molecular mass of the markers used
is indicated
VHH(2) Endoglycosidase H treatment FMDV neutralization (mg/ml)
M180shVI-12 − 0.008
M180shVI-12 + 1
M200shVI-12 − 0.016
M200shVI-12 + 1
M180 − 0.22
M200 − 0.059
VI-12 − >10
a
VI-12 + >1
Table 2 Effect of VHH2 glyco-
sylation on FMDV neutralization
+ endoglycosidase H treatment,
− mock incubation
aNo neutralization at the highest
VHH concentration used
1092 Appl Microbiol Biotechnol (2009) 84:1087–1094ring in yeast, results in their rapid clearance in vivo due to
binding to high-mannose receptors in the liver (Wright and
Morrison 1994). This complicates the immunotherapeutic
use of N-glycosylated FMDV-binding VHHs, which should
be applied parenterally, but not of LT-binding VHHs, which
should be delivered to the intestinal lumen by oral
application. The use of recombinant yeast strains (Hamilton
and Gerngross 2007) or plants (Strasser et al. 2008)t h a ta r e
engineered to produce proteins with human-like glycosyla-
tion for production of glycosylated VHHs could prevent
rapid in vivo clearance after parenteral application.
Normally non-glycosylated VHHs can be converted to
N-glycosylated VHHs by the introduction of potential N-
glycosylation sites by site-directed mutagenesis (Sagt et al.
2000). Thus, the neutralization capacity of VHHs could
possibly be further increased by obtaining glycosylation on
single or even multiple sites that are located distant from
the VHH antigen-binding site. Such an approach has the
additional benefit of an increased yeast production level of
glycosylated VHHs (Sagt et al. 2000).
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